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mortality in patients with hypertension, type 2 diabetes
and microalbuminuria. Three strategies were compared:
early use of irbesartan (begun in subjects with microal-
buminuria), late use of irbesartan (begun only in subjects
with nephropathy), and standard hypertension care (with
comparable blood pressure control). The model was
based on data from the Irbesartan in Reduction of
Microalbuminuria-II study and the Irbesartan and 
Diabetic Nephropathy Trial. Both studies demonstrated
signiﬁcant reductions in the progression of diabetic renal
disease. ESRD-related costs and outcomes were retrieved
from the French-speciﬁc published or ofﬁcial sources.
Cost savings and life years saved were projected for a
hypothetical cohort of 1000 subjects with baseline age 58
years. Future costs and LE were discounted at 3% yearly.
A 25-year time horizon and third party payer perspective
were used. Extensive sensitivity analyses were performed.
RESULTS: When compared to standard care, early use of
irbesartan in 1000 subjects was projected to save €25.7
million (95%CI 16.8–32.3), while late use of irbesartan
was projected to save €9.2 (3.4–14.1) million. Similarly,
early use of irbesartan was estimated to add 796
(520–1050) life years, while late use of irbesartan added
60 (22–92) life years. The superiority of early use of irbe-
sartan over late use and standard care was robust under
a wide range of plausible assumptions. CONCLUSIONS:
Treating patients with hypertension, microalbuminuria
and type 2 diabetes with irbesartan was projected to
extend life and reduce costs. Late use of irbesartan (when
overt nephropathy develops) is also better and less costly
than standard care, but irbesartan should be started
earlier and continued long-term.
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OBJECTIVES: Multi-country trial-based cost-
effectiveness analyses often assume that resource utilisa-
tion and clinical efﬁcacy are not country-speciﬁc, and
apply country-speciﬁc unit costs. We applied economet-
ric methods to estimate country-speciﬁc cost-
effectiveness, adjusting for differences in incremental
resource utilisation and case mix across countries. Results
with and without adjustment are compared and methods
described. METHODS: The TARGET multinational trial
compared cure within 21 days for patients with CAP
between sequential IV/PO moxiﬂoxacin monotherapy
and standard comparators. Unit costs were available for
4 countries (France, Germany, Spain, UK) among 10. A
previously published framework, based on a system of
regression equations, was used to determine treatment
impact on resource use and outcome by country, con-
trolling for baseline characteristics. Clinical efﬁcacy was
held constant across countries, but the impact of cure on
resource utilisation was allowed to vary. Bootstrapping
was also used to estimate uncertainty around country-
speciﬁc cost-effectiveness results. RESULTS: No signiﬁ-
cant inter-country variation in clinical efﬁcacy was
observed (p = 0.9843). Treatment increased the proba-
bility of cure by 5% and the impact of cure on resource
use varied signiﬁcantly across countries (p < 0.0001).
However between-country differences in incremental
resource utilisation were not detected statistically (p =
0.7759) so that unadjusted analysis was also a possible
approach. Using country-speciﬁc unit prices, average
incremental costs per patient non-adjusted and adjusted
were €-266 and €-436 for Germany, €-381 and €-543
for France, €-281 and €+126 for Spain, €-360 and 
€-1192 for UK. The probability that moxiﬂoxacin is cost-
saving was 97% for Germany, 95% for France, 90% for
Spain and 87% for the UK in the non-adjusted analyses
compared to 99%, 66%, 41% and near 100%. CON-
CLUSIONS: Where study treatments impact resource 
use differently across countries or country-speciﬁc CEA
is desired, adjusted results can differ substantially.
Although improved country-speciﬁcity is associated with
increased variation in cost, country-speciﬁc cost-
effectiveness measures may be more informative.
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OBJECTIVE: Development of a user-friendly tool for the
evaluation and improvement of the transferability of eco-
nomic evaluation results. METHODS: We systematically
identiﬁed the factors that may inﬂuence the transfer of
study results and investigated the way they impact trans-
ferability. A transferability decision chart was developed
that includes knock out criteria, a checklist based on the
transferability factors, and methods for improving trans-
ferability and for assessing the uncertainty of transferred
results. The decision chart was applied to various inter-
national cost-effectiveness studies. RESULTS: Economic
evaluation results can be transferred pending the out-
comes of the transferability check and necessary adjust-
ments. The inﬂuence of differences of most transferability
factors can be estimated via the key health economic
determinants capacity utilization, effectiveness, produc-
tivity loss and returns to scale. Depending on the results
of the transferability check an adjustment of the study
results for inﬂation and for differences related to curren-
cies or purchasing power might be sufﬁcient. Otherwise,
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modeling based corrections might be necessary for 
which the (re)-building of the study model is required.
Univariate sensitivity analysis seems appropriate for 
identiﬁcation of the most important adjustments. If not
all relevant study parameters can be substituted with
country speciﬁc ones, multivariate or probabilistic sensi-
tivity analysis appears to be a promising way to quantify
the uncertainty associated with a transfer. If study results
cannot be transferred, the transfer of study models or
designs should be investigated as this can save a sub-
stantial amount of time when conducting a new study.
CONCLUSIONS: The transferability decision chart is a
transparent and user-friendly tool for evaluating and
improving the transferability of economic evaluation
results. For the assessment of transferability, a detailed
method description in the original study is necessary. In
addition, the relevant data should be presented in a non-
aggregated manner for enabling modeling adjustment.
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OBJECTIVES: In making decisions about which health
care interventions to reimburse, cost-effectiveness analy-
ses should directly compare all relevant treatment 
alternatives based on all available data. “Head-to-head”
clinical trials directly comparing all treatment alternatives
are seldom available, requiring the use of indirect trial evi-
dence to make the required comparisons. We illustrate the
use of formal methods to make such comparisons using
two recent cost-effectiveness analyses commissioned for
the National Institute for Clinical Excellence (NICE).
METHODS: The clinical trial evidence available to
inform the evaluations consisted of a mixed set of com-
parisons, such as drugs A vs. B , B vs. C, A vs. D. The
model parameters required to perform the required direct
comparison of the drugs (A vs. B. vs. C.) were estimated
jointly from the available data using a generalized linear
model in a Bayesian hierarchical framework. This was
implemented using Markov Chain Monte Carlo tech-
niques. RESULTS: Direct comparisons of 9 anti-epilepsy
drugs and 5 drugs for the acute-manic episode in bipolar
disorder were undertaken based on data from 27 and 7
trials, respectively. In epilepsy, the analysis showed that,
above a cost-effectiveness threshold of £20,000 per
QALY, the newer adjunct therapies were likely to be cost-
effective, although there was considerable uncertainty in
these results. In bipolar disorder, olanzapine was cost-
effective above a threshold of £7000 per responder. The
use of this analytical approach avoided the need to restrict
the analysis solely to the pairwise treatment comparisons
made in existing trials. Cost-effectiveness acceptability
curves were derived which incorporate the additional
uncertainty associated with the observed heterogeneity
between trials. CONCLUSIONS: The use of formal
analysis of mixed treatment comparisons is likely to play
an important role in reimbursement decisions. Further
research is needed into how additional uncertainty asso-
ciated with unobserved heterogeneity can be incorporated
into cost-effectiveness models.
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OBJECTIVE: To estimate actual use of beneﬁt/risk and
beneﬁt/cost outcomes in health systems decision making.
METHODS: Respondents were selected from public and
private payers, provider organizations, technology ﬁrms,
regulatory agencies and universities in France, Sweden,
UK and US. A survey questionnaire was developed and
pre-tested with 15 people. After modiﬁcation, the survey
was administered to 116 selected people. We asked about
actual use, and examples, by them and their organization
of results from beneﬁt/risk and beneﬁt/cost evaluations in
making decisions on acceptance or rejection of new, and
delisting current, health care technologies. RESULTS: A
total of 104 (89.7%) respondents completed the survey.
Every organization clearly used beneﬁt/risk results in
making decisions about accepting, using, rejecting and
deleting technologies. Surprisingly, nearly every organi-
zation also used economic outcomes to help make deci-
sions. Such results may not have always been formal
beneﬁt/cost evaluations (i.e., about 50% used budget
impact primarily) but there was at the least the recogni-
tion about making trade-offs of beneﬁts and costs among
alternatives. CONCLUSIONS: These results are contrary
to other published studies, based mainly on opinions and
perceptions that found little use of economic analysis in
health care decision making. Post hoc studies of actual
decisions made in UK, Australia of formal analyses, and
in Canada of less formal methods, conﬁrmed use of
beneﬁt/cost results. Measuring actual behavior on use of
economic outcome evaluations in health care decision
making provides different answers than soliciting 
opinions and perceptions of others’ use of these results.
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